FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136602020> ?p ?o ?g. }

• W3136602020 endingPage "e001975" @default.
• W3136602020 startingPage "e001975" @default.
• W3136602020 abstract "Tumors often develop resistance to surveillance by endogenous immune cells, which include natural killer (NK) cells. Ex vivo activated and/or expanded NK cells demonstrate cytotoxicity against various tumor cells and are promising therapeutics for adoptive cancer immunotherapy. Genetic modification can further enhance NK effector cell activity or activation sensitization. Here, we evaluated the effect of the genetic deletion of ubiquitin ligase Casitas B-lineage lymphoma pro-oncogene-b (CBLB), a negative regulator of lymphocyte activity, on placental CD34+ cell-derived NK (PNK) cell cytotoxicity against tumor cells.Using CRISPR/Cas9 technology, CBLB was knocked out in placenta-derived CD34+ hematopoietic stem cells, followed by differentiation into PNK cells. Cell expansion, phenotype and cytotoxicity against tumor cells were characterized in vitro. The antitumor efficacy of CBLB knockout (KO) PNK cells was tested in an acute myeloid leukemia (HL-60) tumor model in NOD-scid IL2R gammanull (NSG) mice. PNK cell persistence, biodistribution, proliferation, phenotype and antitumor activity were evaluated.94% of CBLB KO efficacy was achieved using CRISPR/Cas9 gene editing technology. CBLB KO placental CD34+ cells differentiated into PNK cells with high cell yield and >90% purity determined by CD56+ CD3- cell identity. Ablation of CBLB did not impact cell proliferation, NK cell differentiation or phenotypical characteristics of PNK cells. When compared with the unmodified PNK control, CBLB KO PNK cells exhibited higher cytotoxicity against a range of liquid and solid tumor cell lines in vitro. On infusion into busulfan-conditioned NSG mice, CBLB KO PNK cells showed in vivo proliferation and maturation as evidenced by increased expression of CD16, killer Ig-like receptors and NKG2A over 3 weeks. Additionally, CBLB KO PNK cells showed greater antitumor activity in a disseminated HL60-luciferase mouse model compared with unmodified PNK cells.CBLB ablation increased PNK cell effector function and proliferative capacity compared with non-modified PNK cells. These data suggest that targeting CBLB may offer therapeutic advantages via enhancing antitumor activities of NK cell therapies." @default.
• W3136602020 created "2021-03-29" @default.
• W3136602020 creator A5003517607 @default.
• W3136602020 creator A5008435910 @default.
• W3136602020 creator A5013549427 @default.
• W3136602020 creator A5015824704 @default.
• W3136602020 creator A5016592850 @default.
• W3136602020 creator A5052088230 @default.
• W3136602020 creator A5056397050 @default.
• W3136602020 creator A5075833013 @default.
• W3136602020 creator A5082547105 @default.
• W3136602020 creator A5087308159 @default.
• W3136602020 creator A5091226552 @default.
• W3136602020 date "2021-03-01" @default.
• W3136602020 modified "2023-10-16" @default.
• W3136602020 title "<i>CBLB</i> ablation with CRISPR/Cas9 enhances cytotoxicity of human placental stem cell-derived NK cells for cancer immunotherapy" @default.
• W3136602020 cites W1513014113 @default.
• W3136602020 cites W1539328666 @default.
• W3136602020 cites W1661299775 @default.
• W3136602020 cites W1954860593 @default.
• W3136602020 cites W1969311168 @default.
• W3136602020 cites W1969814796 @default.
• W3136602020 cites W1973425911 @default.
• W3136602020 cites W1995515999 @default.
• W3136602020 cites W2016200146 @default.
• W3136602020 cites W2020646453 @default.
• W3136602020 cites W2027053879 @default.
• W3136602020 cites W2029093937 @default.
• W3136602020 cites W2035833176 @default.
• W3136602020 cites W2036362984 @default.
• W3136602020 cites W2039096179 @default.
• W3136602020 cites W2045664257 @default.
• W3136602020 cites W2056315817 @default.
• W3136602020 cites W2066064912 @default.
• W3136602020 cites W2073300038 @default.
• W3136602020 cites W2088565779 @default.
• W3136602020 cites W2096483233 @default.
• W3136602020 cites W2100482220 @default.
• W3136602020 cites W2105557870 @default.
• W3136602020 cites W2106070783 @default.
• W3136602020 cites W2126153224 @default.
• W3136602020 cites W2131484200 @default.
• W3136602020 cites W2132835748 @default.
• W3136602020 cites W2133321215 @default.
• W3136602020 cites W2238784187 @default.
• W3136602020 cites W2260497117 @default.
• W3136602020 cites W2311158642 @default.
• W3136602020 cites W2396645790 @default.
• W3136602020 cites W2516480116 @default.
• W3136602020 cites W2580332731 @default.
• W3136602020 cites W2738977754 @default.
• W3136602020 cites W2947017746 @default.
• W3136602020 cites W2953336676 @default.
• W3136602020 cites W2954326690 @default.
• W3136602020 cites W2956063089 @default.
• W3136602020 cites W2968330582 @default.
• W3136602020 cites W2998493318 @default.
• W3136602020 cites W3004611567 @default.
• W3136602020 cites W3016048052 @default.
• W3136602020 cites W3118420666 @default.
• W3136602020 cites W4255909846 @default.
• W3136602020 doi "https://doi.org/10.1136/jitc-2020-001975" @default.
• W3136602020 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7986888" @default.
• W3136602020 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33741730" @default.
• W3136602020 hasPublicationYear "2021" @default.
• W3136602020 type Work @default.
• W3136602020 sameAs 3136602020 @default.
• W3136602020 citedByCount "15" @default.
• W3136602020 countsByYear W31366020202021 @default.
• W3136602020 countsByYear W31366020202022 @default.
• W3136602020 countsByYear W31366020202023 @default.
• W3136602020 crossrefType "journal-article" @default.
• W3136602020 hasAuthorship W3136602020A5003517607 @default.
• W3136602020 hasAuthorship W3136602020A5008435910 @default.
• W3136602020 hasAuthorship W3136602020A5013549427 @default.
• W3136602020 hasAuthorship W3136602020A5015824704 @default.
• W3136602020 hasAuthorship W3136602020A5016592850 @default.
• W3136602020 hasAuthorship W3136602020A5052088230 @default.
• W3136602020 hasAuthorship W3136602020A5056397050 @default.
• W3136602020 hasAuthorship W3136602020A5075833013 @default.
• W3136602020 hasAuthorship W3136602020A5082547105 @default.
• W3136602020 hasAuthorship W3136602020A5087308159 @default.
• W3136602020 hasAuthorship W3136602020A5091226552 @default.
• W3136602020 hasBestOaLocation W31366020201 @default.
• W3136602020 hasConcept C203014093 @default.
• W3136602020 hasConcept C2777701055 @default.
• W3136602020 hasConcept C2780674031 @default.
• W3136602020 hasConcept C502942594 @default.
• W3136602020 hasConcept C86803240 @default.
• W3136602020 hasConcept C8891405 @default.
• W3136602020 hasConceptScore W3136602020C203014093 @default.
• W3136602020 hasConceptScore W3136602020C2777701055 @default.
• W3136602020 hasConceptScore W3136602020C2780674031 @default.
• W3136602020 hasConceptScore W3136602020C502942594 @default.
• W3136602020 hasConceptScore W3136602020C86803240 @default.
• W3136602020 hasConceptScore W3136602020C8891405 @default.
• W3136602020 hasIssue "3" @default.
• W3136602020 hasLocation W31366020201 @default.

• next